Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2

• Carlos M. Ferrario

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• Jewell Jessup

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• Mark C. Chappell

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• David B. Averill

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• K. Bridget Brosnihan

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• E. Ann Tallant

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• Debra I. Diz

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

• Patricia E. Gallagher

  From the Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC.

抄録

Background— Angiotensin-converting enzyme 2 (ACE2) has emerged as a novel regulator of cardiac function and arterial pressure by converting angiotensin II (Ang II) into the vasodilator and antitrophic heptapeptide, angiotensin-(1–7) [Ang-(1–7)]. As the only known human homolog of ACE, the demonstration that ACE2 is insensitive to blockade by ACE inhibitors prompted us to define the effect of ACE inhibition on the ACE2 gene. Methods and Results— Blood pressure, cardiac rate, and plasma and cardiac tissue levels of Ang II and Ang-(1–7), together with cardiac ACE2, neprilysin, Ang II type 1 receptor (AT 1 ), and mas receptor mRNAs, were measured in Lewis rats 12 days after continuous administration of vehicle, lisinopril, losartan, or both drugs combined in their drinking water. Equivalent decreases in blood pressure were obtained in rats given lisinopril or losartan alone or in combination. ACE inhibitor therapy caused a 1.8-fold increase in plasma Ang-(1–7), decreased plasma Ang II, and increased cardiac ACE2 mRNA but not cardiac ACE2 activity. Losartan increased plasma levels of both Ang II and Ang-(1–7), as well as cardiac ACE2 mRNA and cardiac ACE2 activity. Combination therapy duplicated the effects found in rats medicated with lisinopril, except that cardiac ACE2 mRNA fell to values found in vehicle-treated rats. Losartan treatment but not lisinopril increased cardiac tissue levels of Ang II and Ang-(1–7), whereas none of the treatments had an effect on cardiac neprilysin mRNA. Conclusions— Selective blockade of either Ang II synthesis or activity induced increases in cardiac ACE2 gene expression and cardiac ACE2 activity, whereas the combination of losartan and lisinopril was associated with elevated cardiac ACE2 activity but not cardiac ACE2 mRNA. Although the predominant effect of ACE inhibition may result from the combined effect of reduced Ang II formation and Ang-(1–7) metabolism, the antihypertensive action of AT 1 antagonists may in part be due to increased Ang II metabolism by ACE2.

収録刊行物

• Circulation

  Circulation 111 (20), 2605-2610, 2005-05-24

  Ovid Technologies (Wolters Kluwer Health)

キーワード

• Physiology (medical)
• Cardiology and Cardiovascular Medicine

詳細情報

• CRID: 1363670321333295616
• NII論文ID: 30022672601
• DOI: 10.1161/circulationaha.104.510461
• ISSN: 15244539
• ISSN: 00097322
• ISSN: http://id.crossref.org/issn/00097322
• Web Site: https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.104.510461
• データソース種別:
  • Crossref
  • CiNii Articles